Citations

Clear

9383 citation(s) found for "Thomas, PS".

P1‐232: Maternal Transmission of Alzheimer's Disease
Heggeli, Kristin, Thomas, Colleen S. , Crook, Julia E. , Graff‐Radford, Neill, Graff‐Radford, Neill

Mayo Clinic

Alzheimer's & Dementia | January 12, 2012 | Volume: 7 | Issue: 4S_Part_5 | Pages: No page available

10.1016/j.jalz.2011.05.512 Get It

Activity of topotecan 21-day infusion in patients with previously treated large cell lymphoma: long-term follow-up of an Eastern Cooperative Oncology Group study (E5493)
Wiernik, Peter H. , Li, Hailun , Weller, Edie, Höchster, Howard S. , Horning, Sandra J., Nazeer, Tipu, Gordon, Leo I. , Minniti, Carl J., Shapiro, Gary R., Cassileth, Peter A., Habermann, Thomas M. , Gordon, Leo I

Mayo Clinic

Leukemia & Lymphoma | January 11, 2012 | Volume: 53 | Issue: 6 | Pages: 1137-1142

10.3109/10428194.2011.643406 | PMID 22111940 Get It

Tissue Factor Pathway Inhibitor Blocks Angiogenesis via Its Carboxyl Terminus
Holroyd, Eric, Delacroix, Sinny , Larsen, Katarína, Harbuzariu, Adriana , Psaltis, Peter J. , Pan, Shuchong, White, Thomas A. , Witt, Tyra A. , Kleppe, Laurel S., Mueske, Cheryl S., Simari, Robert D., Wang, Ling , Mukhopadhyay, Debabrata

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | January 6, 2012 | Volume: 32 | Issue: 3 | Pages: 704-711

10.1161/atvbaha.111.243733 | PMID 22223730 Get It

Objective— Tissue factor pathway inhibitor (TFPI) is the primary regulator of the tissue factor (TF) coagulation pathway. As such, TFPI may regulate the proangiogenic effects of TF. TFPI may also affect angiogenesis independently of TF, through sequences within its polybasic carboxyl terminus (TFPI C terminus [TFPIct]). We aimed to determine the effects of TFPI on angiogenesis and the role of TFPIct. Methods and Results— Transgenic overexpression of TFPI attenuated angiogenesis in the murine hindlimb ischemia model and an aortic sprout assay. In vitro, TFPI inhibited endothelial cell migration. Peptides within the human TFPIct inhibited endothelial cell cord formation and migration in response to vascular endothelial growth factor (VEGF) 165 but not VEGF121. Furthermore, exposure to human TFPIct inhibited the phosphorylation of VEGF receptor 2 at residue Lys951, a residue known to be critical for endothelial cell migration. Finally, systemic delivery of a murine TFPIct peptide inhibited angiogenesis in the hindlimb model. Conclusion— These data demonstrate an inhibitory role for TFPI in angiogenesis that is, in part, mediated through peptides within its carboxyl terminus. In addition to its known role as a TF antagonist, TFPI, via its carboxyl terminus, may regulate angiogenesis by directly blocking VEGF receptor 2 activation and attenuating the migratory capacity of endothelial cells.
Association of Obesity With DNA Mismatch Repair Status and Clinical Outcome in Patients With Stage II or III Colon Carcinoma Participating in NCCTG and NSABP Adjuvant Chemotherapy Trials
Foster, Nathan R. , Yoon, Harry H. , Smyrk, Thomas C. , Kim, George P., Allegra, Carmen J. , Yothers, Greg , Nikcevich, Daniel A., Sargent, Daniel J. , Sinicrope, Frank A. , Sargent, Daniel J , Yothers, Greg

Mayo Clinic

Journal of Clinical Oncology | December 28, 2011 | Volume: 30 | Issue: 4 | Pages: 406-412

10.1200/jco.2011.39.2563 | PMID 22203756 Get It

PurposeAlthough the importance of obesity in colon cancer risk and outcome is recognized, the association of body mass index (BMI) with DNA mismatch repair (MMR) status is unknown.Patients and MethodsBMI (kg/m2) was determined in patients with TNM stage II or III colon carcinomas (n = 2,693) who participated in randomized trials of adjuvant chemotherapy. The association of BMI with MMR status and survival was analyzed by logistic regression and Cox models, respectively.ResultsOverall, 427 (16%) tumors showed deficient MMR (dMMR), and 630 patients (23%) were obese (BMI ≥ 30 kg/m2). Obesity was significantly associated with younger age (P = .021), distal tumor site (P = .012), and a lower rate of dMMR tumors (10% v 17%; P < .001) compared with normal weight. Obesity remained associated with lower rates of dMMR (odds ratio, 0.57; 95% CI, 0.41 to 0.79; P < .001) after adjusting for tumor site, stage, sex, and age. Among obese patients, rates of dMMR were lower in men compared with women (8% v 13%; P = .041). Obesity was associated with higher recurrence rates (P = .0034) and independently predicted worse disease-free survival (DFS; hazard ratio [HR], 1.37; 95% CI, 1.14 to 1.64; P = .0010) and overall survival (OS), whereas dMMR predicted better DFS (HR, 0.59; 95% CI, 0.47 to 0.74; P < .001) and OS. The favorable prognosis of dMMR was maintained in obese patients.ConclusionColon cancers from obese patients are less likely to show dMMR, suggesting obesity-related differences in the pathogenesis of colon cancer. Although obesity was independently associated with adverse outcome, the favorable prognostic impact of dMMR was maintained among obese patients.
Effect of General Anesthesia in Patients With Cerebral Palsy at the Turn of the New Millennium
Wass, C. Thomas, Warner, Mary E. , Castagno, Julie A., Howe, Melinda, Kerber, Kimberly A., Palzkill, Jenna M., Schroeder, Darrell R. , Cascino, Gregory D. , Worrell, Gregory A. , Palzkill, Jenna, Schroeder, Darrell

Mayo Clinic

Journal of Child Neurology | December 21, 2011 | Volume: 27 | Issue: 7 | Pages: 859-866

10.1177/0883073811428378 | PMID 22190505 Get It

The severity of preoperative cerebral palsy appears to correlate directly with postoperative complications. The primary aim of this study was to characterize the frequency of perioperative morbidity and mortality in cerebral palsy patients undergoing anesthesia. This was accomplished by undertaking a systematic review of the Mayo Database. The risk for perioperative adverse events was 63.1% (95% confidence interval 59.8%-66.5%). However, it deserves clarification that hypothermia and clinically significant yet non–life-threatening hypotension represented the majority (80%) of these complications. When these 2 events are excluded, the rate of adverse perioperative events was 13.1% (95% confidence interval 10.8%-15.5%). Risk factors associated with increased risk included American Society of Anesthesiologists physical status score exceeding 2, history of seizures, upper airway hypotonia, general surgery procedures, and adults. Our findings are useful to counsel patients with cerebral palsy, their caregivers, and their guardians regarding the risk of general anesthesia.
Is Leadership a Noun or Verb?
Annesley, Thomas M, Hernandez, James S , Morgan, Angie, Pescovitz, Ora Hirsch, Wright, Ian J.

Mayo Clinic

Clinical Chemistry | December 16, 2011 | Volume: 58 | Issue: 4 | Pages: 667-671

10.1373/clinchem.2011.165639 | PMID 22173645 Get It

Lack of drug interaction between the migraine drug MAP0004 (orally inhaled dihydroergotamine) and a CYP3A4 inhibitor in humans
Kellerman, Donald , Kori, Shashidhar, Forst, Amy, Chang, Jen-Chih, Febbraro, Simone , WuTann, L, Thomas, Tracy, Taylor, Glyn , Dodick, DW

Mayo Clinic

Cephalalgia | December 16, 2011 | Volume: 32 | Issue: 2 | Pages: 150-158

10.1177/0333102411432299 | PMID 22174351 Get It

Background: Dihydroergotamine (DHE), a proven migraine treatment, currently has product labeling warning against concomitant use of CYP3A4 inhibitors because of potential drug interactions. However, no reported studies of such interactions with DHE administered by any route are available. Methods: The pharmacokinetics (PK) of MAP0004, an investigative inhaled DHE formulation, were assessed in human subjects with and without CYP3A4 inhibition by ketoconazole to evaluate the potential for drug interaction, elevation of DHE levels, and increased adverse effects. Results: After MAP0004 alone vs. MAP0004 plus ketoconazole, the DHE maximum concentrations (C max ) and area-under-the-curve (AUC 0–48 and AUC 0–∞ ) were not statistically significantly different nor was the C max of the primary metabolite, 8’-OH-DHE. A difference in 8’-OH-DHE AUCs was observed between MAP0004 with and without ketoconazole; however, the concentrations were very low. MAP0004 was well tolerated after both treatments. Conclusions: This study demonstrated that CYP3A4 inhibition had little to no effect on DHE PK after MAP0004 administration, apparently because of its high systemic and low gastrointestinal bioavailability. CYP3A4 inhibition slowed elimination of the metabolite 8’-OH-DHE, but concentrations were too low to be pharmacologically relevant.
Real-Time Qualitative PCR for 57 Human Adenovirus Types from Multiple Specimen Sources
Buckwalter, Seanne P., Teo, Rose, Espy, Mark J., Sloan, Lynne M., Smith, Thomas F., Pritt, Bobbi S. , Pritt, Bobbi S

Mayo Clinic

Journal of Clinical Microbiology | December 15, 2011 | Volume: 50 | Issue: 3 | Pages: 766-771

10.1128/jcm.05629-11 | PMID 22170906 Get It

ABSTRACT Human adenoviruses (HAdVs) are ubiquitous double-stranded DNA viruses that cause a wide array of diseases in humans including pharyngitis, pneumonia, gastroenteritis, hemorrhagic cystitis, and keratoconjunctivitis. They also cause life-threatening opportunistic infections in immunocompromised individuals and are responsible for outbreaks in certain populations. Diagnosis is traditionally by cell culture or antigen detection methods. However, some HAdVs can take up to 4 weeks to isolate, and diarrheagenic types 40 and 41 will not grow in routine cell culture. Therefore, the goal of this study was to design a rapid, real-time PCR assay to detect all known 57 HAdV types from multiple different specimen sources. Primers and fluorescence resonance energy transfer hybridization probes were designed to target a 185-bp region of the penton base gene of HAdV. The analytical sensitivity was determined to be 10 copies/μl for HAdV types showing exact primer/probe homology in specimen matrix. Using whole-virus strains, the analytical sensitivity for representative HAdV types ranged from 10 −1 to 10 3 50% tissue culture infective dose (TCID 50 )/ml. The assay demonstrated 100% sensitivity and 99% specificity. This real-time PCR assay provides a rapid method for the detection of all 57 known HAdV types from respiratory specimens, blood, stool, urine, and ocular swabs.
Genome-Wide Association Analysis of Ischemic Stroke in Young Adults
Cheng, Yu-Ching , O’Connell, Jeffrey R. , Dueker, Nicole , McArdle, Patrick F. , Sparks, Mary J., Shen, Jess, Laurie, Cathy C. , Doheny, Kimberly F. , Pugh, Elizabeth, Brott, Thomas G. , Brown, Robert D., Nalls, Michael A., Rich, Stephen S. , Worrall, Bradford B. , Anderson, Christopher D. , Biffi, Alessandro , Cortellini, Lynelle, Furie, Karen L., Rost, Natalia S. , Manolio, Teri A. , Kittner, Steven J. , Mitchell, Braxton D. , Cole, John W. , Stine, Oscar Colin , Nelson, Sarah C. , Ling, Hua , Meschia, James F. , Rosand, Jonathan M. , Rich, Stephen S , Mitchell, Braxton D

Mayo Clinic

G3 Genes|Genomes|Genetics | December 14, 2011 | Volume: 1 | Issue: 6 | Pages: 505-514

10.1534/g3.111.001164 | PMID 22384361 Get It

Abstract Ischemic stroke (IS) is among the leading causes of death in Western countries. There is a significant genetic component to IS susceptibility, especially among young adults. To date, research to identify genetic loci predisposing to stroke has met only with limited success. We performed a genome-wide association (GWA) analysis of early-onset IS to identify potential stroke susceptibility loci. The GWA analysis was conducted by genotyping 1 million SNPs in a biracial population of 889 IS cases and 927 controls, ages 15–49 years. Genotypes were imputed using the HapMap3 reference panel to provide 1.4 million SNPs for analysis. Logistic regression models adjusting for age, recruitment stages, and population structure were used to determine the association of IS with individual SNPs. Although no single SNP reached genome-wide significance (P &lt; 5 × 10−8), we identified two SNPs in chromosome 2q23.3, rs2304556 (in FMNL2; P = 1.2 × 10−7) and rs1986743 (in ARL6IP6; P = 2.7 × 10−7), strongly associated with early-onset stroke. These data suggest that a novel locus on human chromosome 2q23.3 may be associated with IS susceptibility among young adults.